Kymera Therapeutics (KYMR) Amortization of Deferred Charges (2020 - 2026)

Kymera Therapeutics (KYMR) has 7 years of Amortization of Deferred Charges data on file, last reported at -$2.7 million in Q1 2026.

• Amortization of Deferred Charges for Q1 2026 came in at -$2.7 million, down 8.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$9.1 million (up 32.39% YoY), and the FY2025 annual result was -$8.9 million, up 36.5% from the prior year.
• Amortization of Deferred Charges slipped to -$2.7 million in Q1 2026 per KYMR's latest filing, from -$2.0 million in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $1.2 million in Q1 2022 and troughed at -$4.0 million in Q2 2024.
• A 5-year average of -$1.8 million and a median of -$2.0 million in 2025 frame the typical range for Amortization of Deferred Charges.
• The sharpest annual moves came in 2023 and 2025: Amortization of Deferred Charges tumbled 1998.28% in 2023, then soared 47.25% in 2025.
• A 5-year view of Amortization of Deferred Charges shows it stood at -$905000.0 in 2022, then tumbled by 40.22% to -$1.3 million in 2023, then tumbled by 157.45% to -$3.3 million in 2024, then jumped by 37.4% to -$2.0 million in 2025, then slumped by 33.5% to -$2.7 million in 2026.
• Business Quant data shows KYMR's Amortization of Deferred Charges at -$2.7 million in Q1 2026, -$2.0 million in Q4 2025, and -$2.2 million in Q3 2025.